Quick Answer
Retatrutide is being studied in a large clinical development program led by Eli Lilly. The most visible studies include the TRIUMPH obesity program, TRANSCEND type 2 diabetes research, and trials focused on obesity-related conditions such as knee osteoarthritis and cardiovascular disease.
The program has already produced important public results. The Phase 2 obesity trial reported up to 24.2% mean weight loss at 48 weeks, TRIUMPH-4 reported 28.7% mean weight loss at 68 weeks, and TRANSCEND-T2D-1 reported significant A1C and weight reductions at 40 weeks.
Explore the AminoRank retatrutide profileReview linked studies, category details, and vendor availability for retatrutide.View retatrutide profileHow The Retatrutide Trial Program Is Organized
Retatrutide clinical trials are designed around a simple idea: test whether a once-weekly triple agonist can improve weight and metabolic outcomes across several populations. The compound activates GIP, GLP-1, and glucagon receptors, which is why it is being studied beyond ordinary weight-loss endpoints.
The TRIUMPH program is the main obesity-focused trial program. ClinicalTrials.gov records include TRIUMPH-1 for obesity or overweight, TRIUMPH-3 for obesity with cardiovascular disease, and TRIUMPH-4 for obesity or overweight with knee osteoarthritis. Lilly has also reported TRANSCEND-T2D-1 results in type 2 diabetes.
Major Trial Areas
The current retatrutide research program is broad. It is not limited to one basic obesity trial.
| Trial area | What it is trying to answer |
|---|---|
| Obesity and overweight | How much weight reduction retatrutide can produce over longer treatment periods. |
| Type 2 diabetes | How retatrutide affects A1C and body weight in people with diabetes. |
| Knee osteoarthritis | Whether weight loss is paired with improvements in pain and function. |
| Cardiovascular disease | How retatrutide performs in higher-risk obesity populations. |
| Obesity-related complications | Whether triple agonism can improve outcomes tied to metabolic disease. |
This is why the clinical-trial story is more interesting than a single headline. Retatrutide is being tested as a metabolic platform, not just as another appetite drug.
TRIUMPH Studies To Know
TRIUMPH-1 is a large obesity or overweight study without type 2 diabetes. It is one of the core trials people follow when asking about future retatrutide availability.
TRIUMPH-3 focuses on participants with obesity and cardiovascular disease. That matters because cardiovascular outcomes and higher-risk populations often shape how metabolic drugs are understood.
TRIUMPH-4 has already produced a major public update. Lilly reported 28.7% mean weight loss at 68 weeks in adults with obesity or overweight and knee osteoarthritis on the 12 mg dose. It also reported improvement in knee pain and physical function measures.
How ClinicalTrials.gov Helps
ClinicalTrials.gov is the best public place to check official study records. A trial page can show the study title, sponsor, recruitment status, eligibility criteria, study locations, endpoints, and estimated dates.
For trial access, the important details are location and eligibility. A person may see a study online and still not qualify because of age, BMI, medical history, medication history, trial-site capacity, or other criteria. Trial enrollment is a screening process, not a simple sign-up form.
For readers looking for a retatrutide clinical trial near them, start with the official trial record and location section. That is more reliable than social media summaries or recycled trial lists.
The most useful fields to read first are not buried in the fine print. Recruitment status tells you whether a study is actively adding participants. Inclusion and exclusion criteria tell you whether the study is even relevant. The locations section tells you whether there is a practical site. Primary and secondary endpoints tell you what the trial is actually designed to measure.
| Trial-record field | Why it matters |
|---|---|
| Recruitment status | Shows whether a study is recruiting, active, completed, or not yet recruiting. |
| Eligibility criteria | Defines who can be screened and who is excluded. |
| Locations | Helps answer "clinical trial near me" questions. |
| Arms and interventions | Shows dose groups, placebo use, and study design. |
| Endpoints | Shows whether the trial is focused on weight, A1C, function, safety, or another outcome. |
What Trial Results Have Shown So Far
The published and reported results explain why retatrutide has become one of the most watched investigational metabolic compounds.
The Phase 2 obesity trial showed dose-dependent weight loss, with the highest dose reaching 24.2% mean weight reduction at 48 weeks. TRIUMPH-4 later reported a larger average weight reduction at 68 weeks in a different population. TRANSCEND-T2D-1 showed that retatrutide can also move A1C in type 2 diabetes research.
Those findings are positive, but each trial has to be read in its own context. A knee osteoarthritis study, a type 2 diabetes study, and an obesity study can all support the same development program while answering different clinical questions.
That context is what makes the program valuable. TRIUMPH-4 is not just another weight-loss readout because knee osteoarthritis pain and function are patient-centered outcomes. TRANSCEND-T2D-1 is not just another obesity readout because A1C reduction changes the metabolic story. The better the trial program gets at showing benefits beyond the scale, the stronger the eventual clinical case becomes.
Trial Status And Approval Status
Clinical trials do not mean a drug is approved. They are the process that generates the evidence regulators review. Retatrutide remains investigational while Lilly continues the clinical program and reports additional data.
That said, the program is moving. Positive Phase 3 updates are a different level of evidence than early mechanism work. The next important milestones are more Phase 3 readouts, full peer-reviewed publications, and any future regulatory filing.
For a dedicated status article, see is retatrutide FDA approved. For trial outcome detail, see retatrutide results.
Research Vendor Context
Clinical-trial participation and research-vendor listings are separate topics. Trials are official studies with eligibility criteria and site oversight. Vendor listings are research-market availability and should be compared by documentation, COAs, reviews, payment options, and shipping.
Compare retatrutide research vendorsBrowse vendors by COAs, reviews, discounts, shipping, and payment options.View retatrutide vendorsFAQ
What retatrutide clinical trials are most important?
TRIUMPH-1, TRIUMPH-3, TRIUMPH-4, and TRANSCEND-T2D-1 are among the most important public retatrutide studies to follow.
How do I find a retatrutide clinical trial near me?
Use ClinicalTrials.gov and review the locations, recruitment status, and eligibility criteria on the official study record.
Are retatrutide clinical trial results published?
Some results are published or reported. The Phase 2 obesity trial is published in NEJM, and Lilly has reported Phase 3 topline updates from TRIUMPH-4 and TRANSCEND-T2D-1.
Does trial participation guarantee retatrutide?
No. Trials can include placebo groups, randomization, eligibility screening, and protocol requirements.